Björkqvist Olle, Rangel Ignacio, Serrander Lena, Magnusson Cecilia, Halfvarson Jonas, Norén Torbjörn, Bergman-Jungeström Malin
Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
School of Medical Sciences, Örebro University, Örebro, Sweden.
PLoS One. 2021 Apr 9;16(4):e0249861. doi: 10.1371/journal.pone.0249861. eCollection 2021.
Fecal microbiota transplantation (FMT) is a highly effective treatment for Clostridioides difficile infection (CDI). However, the fecal transplant's causal components translating into clearance of the CDI are yet to be identified. The commensal bacteria Faecalibacterium prausnitzii may be of great interest in this context, since it is one of the most common species of the healthy gut microbiota and produces metabolites with anti-inflammatory properties. Although there is mounting evidence that F. prausnitzii is an important regulator of intestinal homeostasis, data about its role in CDI and FMT are relatively scarce.
Stool samples from patients with recurrent CDI were collected to investigate the relative abundance of F. prausnitzii before and after FMT. Twenty-one patients provided fecal samples before the FMT procedure, at 2 weeks post-FMT, and at 2-4 months post-FMT. The relative abundance of F. prausnitzii was determined using quantitative polymerase chain reaction.
The abundance of F. prausnitzii was elevated in samples (N = 9) from donors compared to pre-FMT samples (N = 15) from patients (adjusted P<0.001). No significant difference in the abundance of F. prausnitzii between responders (N = 11) and non-responders (N = 4) was found before FMT (P = 0.85). In patients with CDI, the abundance of F. prausnitzii significantly increased in the 2 weeks post-FMT samples (N = 14) compared to the pre-FMT samples (N = 15, adjusted P<0.001). The increase persisted 2-4 months post-FMT (N = 15) compared to pre-FMT samples (N = 15) (adjusted P<0.001).
FMT increases the relative abundance of F. prausnitzii in patients with recurrent CDI, and this microbial shift remains several months later. The baseline abundance of F. prausnitzii in donors or recipients was not associated with future treatment response, although a true predictive capacity cannot be excluded because of the limited sample size. Further studies are needed to discern whether F. prausnitzii plays an active role in the resolution of CDI.
粪菌移植(FMT)是治疗艰难梭菌感染(CDI)的一种高效疗法。然而,粪菌移植中促使CDI清除的因果成分尚未明确。共生菌普拉梭菌在这方面可能备受关注,因为它是健康肠道微生物群中最常见的菌种之一,且能产生具有抗炎特性的代谢产物。尽管越来越多的证据表明普拉梭菌是肠道稳态的重要调节因子,但关于其在CDI和FMT中的作用的数据相对较少。
收集复发性CDI患者的粪便样本,以研究FMT前后普拉梭菌的相对丰度。21名患者在FMT手术前、FMT后2周以及FMT后2 - 4个月提供粪便样本。使用定量聚合酶链反应测定普拉梭菌的相对丰度。
与患者FMT前的样本(N = 15)相比,供体样本(N = 9)中普拉梭菌的丰度有所升高(校正P<0.001)。FMT前,应答者(N = 11)和无应答者(N = 4)之间普拉梭菌的丰度无显著差异(P = 0.85)。在CDI患者中,与FMT前的样本(N = 15)相比,FMT后2周的样本(N = 14)中普拉梭菌的丰度显著增加(校正P<0.001)。与FMT前的样本(N = 15)相比,FMT后2 - 4个月(N = 15)普拉梭菌丰度的增加依然持续(校正P<0.001)。
FMT可增加复发性CDI患者中普拉梭菌的相对丰度,且这种微生物变化在数月后仍持续存在。尽管由于样本量有限不能排除真正的预测能力,但供体或受体中普拉梭菌的基线丰度与未来的治疗反应无关。需要进一步研究以确定普拉梭菌在CDI的缓解中是否发挥积极作用。